[The pathologist's perspective on the PCPT trial].
The PCPT (Prostate Cancer Prevention Trial) trial which compared 5 mg/d of finastéride to placebo in men over 55 years old showed that active treatment reduced the incidence of prostate cancer from 24.4 to 18.4%. Paradoxically, the incidence of high grade cancers (Gleason score > or = 7) was higher in the finasteride group (6.4%) than in the placebo group (5.1%). Histological interpretation of the radical prostatectomy specimens showed an overestimation of Gleason score on biopsy both in the finasteride and placebo group. The high grade cancers on total prostatectomy specimens were not more aggressive in the finasteride arm than in the placebo arm. There is no argument to suggest that long term finasteride may promote the development of highly aggressive cancer. Urologists must clearly be aware that finasteride treatment may result in morphological changes in order to inform the pathologist that this drug is being taken. If a prostate cancer with a Gleason score > or = 7 is diagnosed in a treated patient, the pathologist will perform a double reading of the slides to confirm the score.
Molinié
V
V
Service de Pathologie, Hôpital Saint-Joseph, 185 Rue Raymond-Losserand, Paris, France. vmolinie@hpsj.fr
Allory
Y
Y
D015982:Bias; D001706:Biopsy; D018890:Chemoprevention; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010336:Pathology / Q000592:standards; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic
D004791:Enzyme Inhibitors; D018120:Finasteride